临床肝胆病杂志
臨床肝膽病雜誌
림상간담병잡지
CHINESE JOURNAL OF CLINICAL HEPATOLOGY
2015年
4期
573-577
,共5页
李猛%李志艳%田江克%董晓宇%刘洋%李晨%袁明星%赵红伟
李猛%李誌豔%田江剋%董曉宇%劉洋%李晨%袁明星%趙紅偉
리맹%리지염%전강극%동효우%류양%리신%원명성%조홍위
肝肿瘤%导管消融术%治疗结果
肝腫瘤%導管消融術%治療結果
간종류%도관소융술%치료결과
liver neoplasms%catheter ablation%treatment outcome
目的:探讨超声引导下经皮射频消融治疗邻近横膈部原发性肝癌的安全性及有效性。方法收集2011年1月至2014年10月解放军三〇二医院行超声引导经皮射频消融治疗的患者277例,共计362个原发性肝癌病灶,根据入组标准选择其中66例(共71个邻近横膈部病灶)作为研究组,95例(共114个位于肝实质病灶)作为对照组。比较两组患者病灶治疗术后肿瘤灭活率、局部肿瘤进展发生率和并发症发生情况。计量资料两组间比较采用独立样本t检验,计数资料两组间比较采用χ2检验。结果术后1个月,增强CT或磁共振成像显示研究组65个病灶(91.5%)及对照组107个病灶(93.9%)完全灭活,两组比较差异无统计学意义(χ2=0.36,P=0.55);随访术后研究组与对照组发生局部肿瘤进展的病灶分别为16.9%、13.2%,两组比较差异无统计学意义(χ2=0.49,P=0.48)。研究组术后有22例患者出现副反应,对照组有37例患者出现副反应,两组比较差异无统计学意义(χ2=2.60,P=0.11)。结论超声引导经皮射频消融治疗膈顶部肝肿瘤是安全、有效的。
目的:探討超聲引導下經皮射頻消融治療鄰近橫膈部原髮性肝癌的安全性及有效性。方法收集2011年1月至2014年10月解放軍三〇二醫院行超聲引導經皮射頻消融治療的患者277例,共計362箇原髮性肝癌病竈,根據入組標準選擇其中66例(共71箇鄰近橫膈部病竈)作為研究組,95例(共114箇位于肝實質病竈)作為對照組。比較兩組患者病竈治療術後腫瘤滅活率、跼部腫瘤進展髮生率和併髮癥髮生情況。計量資料兩組間比較採用獨立樣本t檢驗,計數資料兩組間比較採用χ2檢驗。結果術後1箇月,增彊CT或磁共振成像顯示研究組65箇病竈(91.5%)及對照組107箇病竈(93.9%)完全滅活,兩組比較差異無統計學意義(χ2=0.36,P=0.55);隨訪術後研究組與對照組髮生跼部腫瘤進展的病竈分彆為16.9%、13.2%,兩組比較差異無統計學意義(χ2=0.49,P=0.48)。研究組術後有22例患者齣現副反應,對照組有37例患者齣現副反應,兩組比較差異無統計學意義(χ2=2.60,P=0.11)。結論超聲引導經皮射頻消融治療膈頂部肝腫瘤是安全、有效的。
목적:탐토초성인도하경피사빈소융치료린근횡격부원발성간암적안전성급유효성。방법수집2011년1월지2014년10월해방군삼〇이의원행초성인도경피사빈소융치료적환자277례,공계362개원발성간암병조,근거입조표준선택기중66례(공71개린근횡격부병조)작위연구조,95례(공114개위우간실질병조)작위대조조。비교량조환자병조치료술후종류멸활솔、국부종류진전발생솔화병발증발생정황。계량자료량조간비교채용독립양본t검험,계수자료량조간비교채용χ2검험。결과술후1개월,증강CT혹자공진성상현시연구조65개병조(91.5%)급대조조107개병조(93.9%)완전멸활,량조비교차이무통계학의의(χ2=0.36,P=0.55);수방술후연구조여대조조발생국부종류진전적병조분별위16.9%、13.2%,량조비교차이무통계학의의(χ2=0.49,P=0.48)。연구조술후유22례환자출현부반응,대조조유37례환자출현부반응,량조비교차이무통계학의의(χ2=2.60,P=0.11)。결론초성인도경피사빈소융치료격정부간종류시안전、유효적。
Objective To investigate the safety and efficacy of ultrasound (US)-guided percutaneous radiofrequency ablation (RFA)for primary hepatic carcinoma adjacent to the diaphragm.Methods This study included 277 patients with 362 lesions of primary hepatic carci-noma managed with US-guided percutaneous RFA in 302 Hospital of PLA from January 2011 to October 2014.Sixty-six patients with 71 hepatocellular carcinomas (HCCs)located less than 5 mm from the diaphragm were in study group,and 95 patients with 1 14 HCCs located more than 10 mm from the hepatic surface were in control group.The patients′symptoms and complications were observed after the therapy. The complete ablation rate,local tumor progression rate,and complication rate were compared between the two groups.Comparison of con-tinuous data between the two groups was made by independent-samples t test,while comparison of categorical data was made by chi -square test.Results At one month after operation,65 (91.5%)of 71 tumors in the study group and 107 (93.9%)of 114 tumors in the control group achieved complete ablation,according to contrast-enhanced CT and MRI,and there was no significant difference between the two groups (χ2 =0.36,P=0.55).The postoperative follow-up showed that the local tumor progression rates in the study group and con-trol group were 16.9% and 13.2%,respectively,without significant difference between the two groups (χ2 =0.49,P=0.48).In the study group,22 patients developed adverse reactions,versus 37 patients in the control group (χ2 =2.60,P=0.1 1 ).Conclusion US-guided percutaneous RFA is a safe and effective means for the treatment of primary hepatic carcinoma adjacent to the diaphragm.